PDF(Pubmed)
Abstract：
Hashimoto\'s encephalopathy (HE) has been a poorly understood disease. It has been described in all age group, yet, there is no specific HE marker. Additionally, the treatment data in the available studies are frequently divergent and contradictory. Therefore, the aim of our systematic and critical review is to evaluate the diagnosis and treatment of HE in view of the latest findings. The databases browsed comprised PubMed, Scopus, and Google Scholar as well as Cochrane Library, and the search strategy included controlled vocabulary and keywords. A total of 2443 manuscripts were found, published since the beginning of HE research until February 2024. In order to determine validity of the data collected from studies, bias assessment was performed using RoB 2 tool. Ultimately, six studies were included in our study. HE should be considered in the differential diagnosis in patients with psychiatric and neurological symptoms. According to our findings, negative thyroid peroxidase antibodies (anti-TPOs) may represent a valuable parameter in ruling out HE. Nonetheless, this result cannot be used to confirm HE. Furthermore, the proposed anti NH2-terminal-α-enolase (anti-NAE) is non-specific for HE. The effectiveness of glucocorticoid therapy is 60.94%, although relapse occurs in 31.67% of patients following the treatment. Our review emphasizes the significance of conducting further large-scale research and the need to take into account the potential genetic factor.
摘要：
桥本脑病（HE）是一种鲜为人知的疾病。在所有年龄组都有描述，然而，没有特定的HE标记。此外,现有研究中的治疗数据往往存在分歧和矛盾.因此,我们的系统性和批判性综述旨在根据最新发现评估HE的诊断和治疗.浏览的数据库包括PubMed，Scopus,谷歌学者以及科克伦图书馆，搜索策略包括受控的词汇和关键词。共发现2443份手稿,自HE研究开始以来一直发表到2024年2月。为了确定从研究中收集的数据的有效性，使用RoB2工具进行偏倚评估.最终,我们的研究包括6项研究.在有精神和神经症状的患者的鉴别诊断中应考虑HE。根据我们的发现,阴性甲状腺过氧化物酶抗体（抗TPO）可能是排除HE的一个有价值的参数。尽管如此，此结果不能用于确认HE。此外，所提出的抗NH2-末端-α-烯醇化酶(抗-NAE)对HE是非特异性的。糖皮质激素治疗的有效率为60.94%,尽管31.67%的患者在治疗后复发。我们的评论强调了进行进一步大规模研究的重要性以及考虑潜在遗传因素的必要性。
